Antoine Lemaire

Dr. Antoine Lemaire

Centre Hospitalier de Valenciennes, Valenciennes, Hauts-de-France, France
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Neurophysiologie Clinique
Verified
Journal Article
Closed access
FVFrederic JF VISEUX
Frederic JF VISEUX
Antoine LemaireAntoine Lemaire
Antoine Lemaire
FBFranck Barbier
Franck Barbier
PCPascal Charpentier
Pascal Charpentier
SLSebastien Leteneur
Sebastien Leteneur
PVPhilippe Villeneuve
Philippe Villeneuve

11 May 2019 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
CMCaroline Maindet
Caroline Maindet
ABAlexis Burnod
Alexis Burnod
CMChristian Minello
Christian Minello
BGBrigitte George
Brigitte George
GAGilles Allano
Gilles Allano
Antoine LemaireAntoine Lemaire
Antoine Lemaire

24 May 2019 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
BGBrigitte George
Brigitte George
CMChristian Minello
Christian Minello
GAGilles Allano
Gilles Allano
CMCaroline Maindet
Caroline Maindet
ABAlexis Burnod
Alexis Burnod
Antoine LemaireAntoine Lemaire
Antoine Lemaire

11 May 2019 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
CMChristian Minello
Christian Minello
BGBrigitte George
Brigitte George
GAGilles Allano
Gilles Allano
CMCaroline Maindet
Caroline Maindet
ABAlexis Burnod
Alexis Burnod
Antoine LemaireAntoine Lemaire
Antoine Lemaire

15 May 2019 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
Antoine LemaireAntoine Lemaire
Antoine Lemaire
BGBrigitte George
Brigitte George
CMCaroline Maindet
Caroline Maindet
ABAlexis Burnod
Alexis Burnod
GAGilles Allano
Gilles Allano
CMChristian Minello
Christian Minello

21 December 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
Chloé MelchiorChloé Melchior
Chloé Melchior
CDCharlotte Desprez
Charlotte Desprez
FWFabien Wuestenberghs
Fabien Wuestenberghs
ALAnne-Marie Leroi
Anne-Marie Leroi
Antoine LemaireAntoine Lemaire
Antoine Lemaire
GGGuillaume Goucerol
Guillaume Goucerol
Objective: We aimed to determine the burden of opioid consumption in a cohort of patients with functional gastrointestinal disorders.Methods: All patients diagnosed with functional gastrointestinal disorders and referred to our university hospital were evaluated from 2013 to the beginning of 2019. Irritable bowel syndrome and functional dyspepsia diagnoses were determined according to Rome criteria and severity according to irritable bowel syndrome severity scoring system. Vomiting was quantified using a 5-point Likert scale, and constipation severity was measured using the Knowles-Eccersley-Scott-Symptom questionnaires. Quality of life was quantified by the GastroIntestinal Quality of Life Index. Patients were categorized as being treated on a chronic basis with either tramadol, step II opioids, step III opioids or as being opioid-free.Results: 2933 consecutive patients were included. In our cohort, 12.5% had only irritable bowel syndrome, 39.3% had only functional dyspepsia, 24.9% had a combination of both, and 23.4% had other functional gastrointestinal disorders. Among them, the consumption of tramadol, step II (tramadol excluded) and step III opioids was 1.8, 1.3 and 0.3 % respectively in 2013 and 4.3, 3.4 and 1.9% in 2018 (p < 0.03). Opioid consumption was associated with increased vomiting (p = 0.0168), constipation (p < 0.0001), symptom severity (p < 0.001), more altered quality of life (p < 0.0001) and higher depression score (p = 0.0045).Conclusion: In functional gastrointestinal disorders, opioid consumption has increased in the last years and is associated with more GI symptoms (vomiting, constipation and GI severity), higher depression and more altered quality of life.